Every year a select group of new drugs promise not to just add an extra option for patients. Some of these blockbuster-to-be drugs are expected to dramatically reshape existing markets, often by stealing away more than their share from the therapies that already dominate in a field.
Here are 7 being billed as blockbuster buster.
The analysts at Cortellis didn’t just forecast 2023 sales for the most promising new drugs slated to win an approval this year, or already prepped for launch. They also calculated how they would do against the dominant drugs in their class. And many times their success will weigh heavily on the chart-topping drugs in their field.
Here’s a summary, based on the new report.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription